Supporting patients' decision making about clinical trials may enhance trial participation. To date, few theory-based interventions have been tested to address this issue. The objective of the current study was aimed to evaluate the effect of a multimedia psychoeducation (MP) intervention, relative to a print education (PE) intervention, on patients' decision support needs and attitudes about clinical trials. METHODS: Patients with cancer who were eligible for participation in a National Cancer Institute therapeutic cancer clinical trial were recruited through the nationwide University of Rochester Cancer Center National Cancer Institute Community Oncology Research Program from 2014 to 2016 and were randomized to the MP or PE intervention. Assessments at baseline (before intervention), postintervention, and at a 2-month follow-up visit included patients' decision support needs, attitudes regarding clinical trials, and clinical trial participation. RESULTS: In total, 418 patients with various types of cancer were recruited (ages 26-89 years). Relative to the PE intervention, the MP intervention did not significantly affect decision support needs. However, patients in the MP arm reported significantly more positive attitudes about clinical trials and were more likely to participate in a clinical trial than those in the PE arm (69% vs 62%; P = .01). Furthermore, an improvement in attitudes about clinical trials significantly mediated the effect of the intervention on participation in clinical trials. CONCLUSIONS: The MP intervention was able to improve patient attitudes toward clinical trials compared with the PE intervention, and this improvement led to increased rates of participation in trials. The MP intervention could be disseminated to improve attitudes about clinical trials among patients with cancer. Cancer 2018;124:4504-4511.
INTRODUCTION
Clinical trials are a critical component in the development of innovative and effective cancer treatments. However, many patients have an incomplete or inaccurate understanding of the purpose, structure, and constraints of clinical trials. This lack of understanding could contribute to a general reluctance to participate in trials. 1 Only an estimated 27% of patients with cancer in the United States will have the option to enroll in a clinical trial, and low rates of participation cause up to 20% of registered cancer clinical trials to prematurely close. [1] [2] [3] Although many informational brochures, guides, and websites have been developed to inform potential participants about cancer clinical trials, few intervention studies have been conducted to test the efficacy of these materials. 4 The intervention studies that have been conducted have highlighted the limited impact of informational materials on relevant patient outcomes, such as attitudes toward clinical trials and decision-making processes regarding clinical trials. 4 A key criticism of much of this research is that it has not been driven by theory or an in-depth understanding of barriers to possible clinical trial participation. 4 Previous research suggests that both logistical and attitudinal barriers influence patients' willingness to participate in clinical trials. 5, 6 Logistical barriers include out-of-pocket medical costs, distance from the treatment center, or occupational or caregiving responsibilities that restrict a patient's ability to participate in a clinical trial. 5, 7, 8 Attitudinal barriers, which have been the focus of considerable study, 5, 6, [9] [10] [11] [12] [13] [14] [15] [16] [17] are comprised of negative perceptions, misperceptions,
Cancer December 1, 2018 and positive attitudes, such as altruism, regarding clinical trials. 5, 9, 16 Observational studies consistently identify the attitudes of patients with cancer about clinical trials as a primary factor contributing to their decision making about participation. 11, 18, 19 An important feature of attitudes is that they are modifiable and thus represent an excellent target for intervention efforts. 20 On the basis of the Ottawa Decision Support Framework 21 and the Theory of Planned Behavior, 20 it may be hypothesized that educational interventions can have a positive impact on decision making about clinical trial participation and can improve the attitudes of patients with cancer toward clinical trials. 11, 18, 19 In the Ottawa Decision Support Framework (a widely used model for studying health care decision making), effective decision support resolves decisional needs and results in better preparedness for decision making. 22, 23 In the Theory of Planned Behavior, engagement in health-related behaviors is guided by beliefs or attitudes about consequences of the behavior, beliefs or attitudes about the expectations of others regarding the behavior, and beliefs or attitudes about barriers and facilitators of the behavior. 20 An intervention that could provide information, address decisional needs, and improve attitudes in these areas might help to clarify the decision-making process for patients who are considering clinical trials. It is important that any such intervention acknowledges that participating in a clinical trial is a patient's choice and provides balanced information to help clarify this decision without coercing or unduly influencing the patient in any way.
We developed a multimedia psychoeducation (MP) intervention [24] [25] [26] [27] [28] designed to improve patients' attitudes toward clinical trials as well as provide education about clinical trials. 29 Previous educational interventions have focused primarily on providing knowledge about clinical trials 30, 31 and have not proven effective in changing patients' attitudes. 24, 25 Our intervention is described as "psychoeducational" given its combined focus on knowledge and attitude change, and it uses a multimedia approach involving video and audio testimonials from patients that has been shown to be more effective than print alone in previous trials of attitude change. [32] [33] [34] Preliminary evaluation of the intervention provided strong evidence that it is effective in improving the attitudes of patients with cancer toward clinical trials in limited samples as well as their hypothetical willingness to participate in clinical trials. 34 The next logical step, based on the Ottawa Decision Support Framework and the Theory of Planned Behavior, is to evaluate the impact of the MP intervention on preparedness for decision making and attitudes about clinical trial participation in a larger, more generalizable sample of patients who are eligible for a cancer clinical trial. The objectives of the current study were to compare the effect of the MP intervention versus a print education (PE) intervention on: 1) decision support factors, 2) attitudes toward clinical trials, and 3) willingness to participate in clinical trials. This trial was registered at clinicaltrials.gov (National Clinical Trial NCT02054715).
MATERIALS AND METHODS

Design
Patients with cancer who were eligible for participation in therapeutic cancer clinical trials were recruited nationwide by research coordinators at community-based oncology clinics affiliated with the University of Rochester Cancer Center National Cancer Institute Community Oncology Research Program (NCORP) Research Base from 2014 to 2016. Patients were randomly assigned 1:1 by computergenerated, random blocks of 4 to 1 of 2 intervention conditions: 1) a PE condition that included an informational booklet, or 2) an MP condition that included a DVD and a companion booklet. The study biostatistician maintained the randomization table. Patient-reported outcomes were assessed before intervention delivery (baseline), 3 to 7 days after intervention delivery (postintervention), and 49 to 56 days after intervention delivery (2-month follow-up). These time points were chosen based on common clinical follow-up times and on our previous research. 34 The Institutional Review Board of the University of Rochester approved the protocol, and all patients provided written informed consent. This trial is registered with clinicaltrials.gov as National Clinical Trial NCT02054715.
Intervention
Patients randomized to the PE intervention met with an NCORP site study coordinator who provided them with the National Cancer Institute booklet Taking Part in Cancer Treatment Studies, which was chosen because it is widely available and served as a stronger control than receiving nothing at all. The booklet consists primarily of information about the nature and conduct of cancer clinical trials (eg, explanations of different phases and oversight by institutional review boards). Patients randomized to the MP intervention met with a coordinator who provided them with a DVD and booklet, both titled Clinical Trials: Are They Right for You? 35 The objectives of the MP materials were to prepare patients for possible decision making, foster an open-minded attitude, and motivate patients to learn more about clinical trial Cancer December 1, 2018 participation using examples from other patients' experiences. The coordinator stayed with participants in both arms to ensure that they read or watched the study materials and to answer questions. For more information on the details of the PE and MP interventions, please see the Supporting Methods.
Participant Eligibility
To participate in this trial, participants must have been: diagnosed with cancer, eligible for a specific phase 2 or 3 therapeutic clinical trial open for enrollment at the participating NCORP site, informed of their eligibility for a specific phase 2 or 3 therapeutic clinical trial by a member of their cancer care team, age ≥18 years, able to speak and read English, and capable of providing written informed consent. Participants must not: have been asked previously to participate in another therapeutic cancer clinical trial; have already made a decision to participate in a phase 2 or 3 therapeutic clinical trial; have documented or observable visual, auditory, psychiatric, or neurologic disorders that would interfere with study participation (eg, blindness, deafness, psychosis, or dementia), or been eligible only for a phase 1 trial.
Measures
All measures chosen were used in previous research on cancer clinical trials. 34 
Demographic and clinical characteristics
Self-reported demographic characteristics included: age, race, sex, ethnicity, household income, years of education, and marital status. Clinical information collected by chart review included: cancer type and stage, date of diagnosis, and types of cancer treatments (eg, surgery, chemotherapy) received in the 12 months before study enrollment.
Decision support factors
On the basis of the Ottawa Decision Support Framework, participants were asked to report on their preparedness for decision making (assessed postintervention). The Preparation for Decision Making Scale is a valid and reliable, 10-item self-report measure in which respondents rate the usefulness of materials provided to patients in preparing them to communicate with their health care provider and make a health care decision (higher scores indicate better support). 22 In the current study, this scale was keyed to the decision about therapeutic clinical trial participation.
Attitudes toward clinical trial participation
Positive and negative attitudes toward clinical trial participation were measured at baseline and postintervention using the Clinical Trials Attitudes Scale, 36 a 20-item selfreport measure. Items were rated on a Likert-type scale from zero to 4. A total score was calculated as the mean of all items, and higher scores indicated more positive attitudes about clinical trials.
Cancer clinical trial participation
Patients' decisions about clinical trial participation were measured by self-report at follow-up and were confirmed by chart review. The self-report items asked whether the patient had been provided a written informed consent form for clinical trial participation and whether the patient did or did not sign the consent form. The patients' medical charts were reviewed to confirm specific actions related to clinical trial discussion and consenting.
Statistical Analyses
On the basis of a priori power analyses, a sample size of 176 participants per condition (N = 352) was sufficient to detect a 0.30 effect size on the Preparation for Decision Making Scale with 80% power at the .05 significance level. 21, 22, 37, 38 Our achieved sample size was N = 418.
To test the hypotheses that MP would result in better preparedness for decision making as well as more positive attitudes regarding clinical trial participation, we conducted linear mixed models with scores on relevant scales as the outcomes and intervention arm (MP or PE) as the predictor; demographic and clinical covariates that differed between intervention arms at P < .15 were included as covariates. NCORP site initially was included as a random effect and was removed from the model if it was nonsignificant.
To conduct exploratory analysis regarding the effects of intervention assignment on clinical trial participation, data were entered into 2 × 2 (arm [MP or PE] × clinical trial participation [yes or no/still deciding]) and 2 × 3 (arm [MP or PE] × clinical trial participation [yes, or no, or still deciding]) contingency tables and analyzed using chi-square tests. To test whether the effects of intervention assignment on clinical trial participation were mediated by intervention effects on attitudes, path coefficients for the mediator model and bootstrap confidence intervals for effects were estimated using methods described by Preacher and Hayes. 39 For the estimates, we used diagonally weighted least squares, which are suitable for binary variables, and bootstrap-based standard errors and 95% confidence intervals (10,000 bootstrap resamples).
Because no bias was detected in the pattern of missing data, we applied the Jamshidian and Jalal nonparametric test for data "missing completely at random" 40 and used complete-case analyses for all outcomes. We used 
RESULTS
Participant Characteristics
On average, participants were a mean ±standard deviation age of 61.5 ± 11.9 years, and 255 (61%) were women. Most patients were white/Caucasian (89%), and only 1.9% reported a Hispanic/Latino ethnicity. The most commonly reported annual household income was $60,000 to $100,000 (19.7%), the most common education was partial college (32.7%), and the most common marital status was currently married (59.1%). The most common cancer type was breast (29.2%), and the average ± standard deviation time since cancer diagnosis was 10.6 ± 28.5 months. Most patients had received at least 1 type of cancer treatment in the 12 months before enrollment on the trial, with surgery being the most common (43.5%). Because both time since diagnosis and level of education differed significantly between the MP and PE arms, these factors were included as Cancer December 1, 2018 covariates in our linear models. For further details, see Table 1 and the Consolidated Standards of Reporting Trials (CONSORT) diagram in Figure 1 .
Effect of Intervention on Decision Support Factors
There were no significant differences between the MP and PE arms on the Preparation for Decision Making Scale after the intervention. Participants in both arms reported high preparedness for decision making (MP vs PE: mean, 71.16 vs 71.26). In separate analysis of covariance (ANCOVA) models predicting a change in decision-making preparedness, intervention arm did not emerge as a significant predictor.
Effect of Intervention on Attitudes
At the baseline assessment, the mean score on the Clinical Trials Attitudes Scale was 3.63 in the MP arm and 3.66 in the PE arm, from a maximum possible score of 4 (with 4 indicating the most positive attitudes; P = .56). At the postintervention assessment, the mean score on the Clinical Trials Attitudes Scale was 3.80 in the MP arm and 3.71 in the PE arm (P = .04). In the ANCOVA model evaluating change in attitude, the mean changes for the arms were significantly different (P < .01), with patients randomized to the MP intervention reporting more positive attitudes.
Effect of Intervention on Participation in Clinical Trials
At the 2-month follow-up, 117 of the 170 participants (69%) who had evaluable data and were randomized to the MP arm had enrolled in a clinical trial, whereas 42 (25%) had Opted not to enroll, and 11 (6%) were undecided. By contrast, 119 of the 192 participants (62%) who had evaluable data and were randomized to the PE arm had enrolled in a clinical trial, whereas 69 (36%) had opted not to enroll, and 4 (2%) were undecided. This Figure 1 . This is a Consolidated Standards of Reporting Trials (CONSORT) diagram of the current trial. The study followed the CONSORT guidelines for reporting randomized trials of behavioral and pharmacologic interventions. MP indicates the multimedia psychoeducation intervention; PE, the print education intervention.
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Cancer December 1, 2018 difference was statistically significant when comparing those who enrolled, those who opted not to enroll, and those who were undecided (chi-square statistic, 8.55; P = .01). Patients who were randomized to the MP arm were significantly more likely to enroll in a clinical trial than those who were randomized to the PE arm. The difference between arms was not significant when comparing those who enrolled with those who did not enroll and who were undecided, combined. For percentages and mean differences by intervention arm, see Table 2 .
Mediation of Intervention Effect by Change in Attitude
In the path model examining whether the effects of intervention assignment on clinical trial participation were mediated by intervention effects on attitudes, all path coefficients were statistically significant (see Fig. 2 ). The intervention arm had a significant main effect on both attitudes at postintervention (controlling for attitudes at baseline) and participation in clinical trials at follow-up, whereas attitudes at postintervention had a significant main effect on participation in clinical trials (again controlling for attitudes at baseline). The indirect effect of intervention arm through attitudes at postintervention also was significant (95% confidence interval, 0.01-0.10; P = .05), indicating that a change in attitudes toward clinical trials mediated the effect of intervention arm on clinical trial participation.
DISCUSSION
In the current study, we examined the effect of an MP intervention versus a PE intervention on decisional support and attitudes toward clinical trial participation among patients with cancer. We also explored the effect of intervention assignment on actual clinical trial participation. The findings demonstrated that the brief MP intervention improved patients' attitudes toward clinical trials and also significantly increased actual rates of trial participation, even after controlling for variation in NCORP recruitment sites. This finding supports the premise that knowledge alone (ie, the PE intervention) may not be sufficient to change behavior and that a theory-based video intervention may be more efficacious at changing both attitudes toward behavior and behavior itself. 34 It is noteworthy that our primary hypothesis that the MP intervention would improve preparedness for decision making was not supported. The Ottawa Decision However, participants in the MP arm did report significantly more positive attitudes toward participating in clinical trials and were more likely to enroll in a clinical trial than those in the PE arm. The theory of planned behavior posits that improving attitudes toward a given behavior can increase the likelihood of an individual engaging in that behavior. This mechanism has been supported in studies of behaviors including exercise 41 and smoking cessation. 42 In the current study, we demonstrated that a change in attitudes mediated the effect of intervention arm on enrollment in clinical trials. The efficacy of multimedia messages in changing attitudes is supported by findings from other studies.
32-34
Limitations
The current study had several limitations. First, the sample size for racial and ethnic minorities was very small, precluding further subgroup analysis. The low accrual rate of minorities in clinical trials is well documented, 43, 44 and a negative attitude toward clinical trials is among the reasons given for nonparticipation. 45 Therefore, delivering the MP intervention to racial and ethnic minority groups potentially could have an impact on attitudes toward clinical trials in these hard-to-reach populations as well as other groups of patients with cancer who have historically low rates of participation in research. In addition, participants who consented to this study may have been more likely by default to participate in a clinical trial, and those who declined participation may have differed in their response to the MP and PE interventions. We did not collect data on comorbidities, which may have influenced patients' willingness to participate in clinical trials. Finally, the effect size for the MP intervention was significant but small, and ways to further optimize this intervention could be a subject of future research.
Conclusion
The current study demonstrated that the MP intervention improved the quality of decision making among patients with cancer who were asked to consider clinical trial participation. These results indicate that our novel intervention is ready for dedicated implementation and dissemination testing to optimize integration into routine clinical care, thereby addressing a critical barrier to the successful development of effective cancer treatments.
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